Prediction of overall survival in pancreatic cancer based on a twenty-four-gene risk model associated with lymph node metastasi
Contact us if these videos are not relevant.
Contact us if these videos are not relevant.
View abstract on PubMed
Summary
This summary is machine-generated.A novel 24-gene risk score effectively predicts pancreatic adenocarcinoma (PAAD) patient survival. This tool stratifies patients into low- and high-risk groups, aiding clinical prognosis and treatment decisions for this deadly cancer.
Area Of Science
- Oncology
- Genomics
- Biostatistics
Background
- Pancreatic adenocarcinoma (PAAD) is a significant cause of cancer mortality.
- Accurate prediction of overall survival is critical for PAAD patient management.
- Identifying robust prognostic biomarkers is essential for improving patient outcomes.
Purpose Of The Study
- To develop and validate a gene-based risk score for predicting PAAD patient prognosis.
- To assess the accuracy of the risk score in stratifying patients into different survival risk groups.
- To identify independent prognostic factors for PAAD.
Main Methods
- Construction and validation of a 24-gene risk score model.
- Survival analysis using Kaplan-Meier curves on independent patient cohorts (GEO datasets).
- Multivariate Cox regression analysis to identify independent risk factors and assess model performance using AUC values.
Main Results
- The 24-gene risk score accurately stratified PAAD patients into low- and high-risk groups with significant survival differences (P < .01).
- The risk score demonstrated high prognostic accuracy: 1-year AUC 0.81, 2-year AUC 0.85, 3-year AUC 0.92.
- N stage and the 24-gene risk score were identified as independent prognostic factors. A nomogram incorporating these factors showed good performance (AUCs 0.76-0.86).
Conclusions
- A validated 24-gene risk score serves as a powerful tool for predicting PAAD patient prognosis.
- The developed risk score and nomogram can assist clinicians in personalized risk assessment and treatment planning for PAAD.
- This study provides a valuable genomic biomarker for improving the clinical management of pancreatic cancer.
Contact us if these videos are not relevant.
Contact us if these videos are not relevant.
